DLL4 and cancer: Consequently, various approaches have been developed to target the Dll4/Notch pathway including anti-Dll4 antibodies, Dll4-Fc and Notch-Fc decoys, DNA vaccination, anti-Notch antibodies, as well as γ-secretase inhibitors and anti-Dll4/Notch therapy is currently evaluated in clinical trials for cancer therapy [9].